{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:23:48Z","timestamp":1780079028775,"version":"3.54.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment-resistant bipolar depression (TRBD) is a major challenge in psychiatric practice, leading to marked impairment in functioning and quality of life, and increased healthcare utilization. Despite its clinical relevance, consensus on diagnostic criteria and evidence-based therapeutic strategies remains limited. Within the framework of personalized medicine, identifying effective and well-tolerated options for this heterogeneous population is important. This study evaluates the short-term effectiveness and tolerability of lurasidone as an adjunctive treatment in TRBD, with attention to its potential role in tailoring interventions to individual clinical profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This four-week, retrospective, multicentre observational study included patients with TRBD receiving lurasidone in augmentation to ongoing pharmacological treatment. Dosages were adjusted according to clinical judgement. Symptom severity was assessed with the 17-item Hamilton Depression Rating Scale (HAM-D), Young Mania Rating Scale (YMRS), and Hamilton Anxiety Rating Scale (HAM-A). Changes from baseline to endpoint were analyzed with repeated measures ANOVA; missing data were managed with the Last Observation Carried Forward (LOCF) method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty patients were enrolled. The mean final lurasidone dose was 51.2 mg\/day. Significant improvements were observed across all scales, with consistent reductions in depressive and anxiety symptoms. Clinical response was achieved in 33.3% of participants, while remission occurred in 3.3%. Adverse events were reported by 68.3% of completers, all mild to moderate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lurasidone appears to be an effective and generally well-tolerated adjunctive option for TRBD. However, remission rates remained low, underscoring the need for further research. In this perspective, lurasidone may contribute to more individualized treatment strategies for difficult-to-treat patients, although confirmatory studies are required to better define its role within precision psychiatry.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1744056","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:42:45Z","timestamp":1771483365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression: a retrospective observational analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Giorgia","family":"Porceddu","sequence":"first","affiliation":[{"name":"Department of Neurosciences, San Luigi Gonzaga University Hospital","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Pessina","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Community Mental Health Center, Local Health Unit of Cuneo 2","place":["Cuneo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Ignazio","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Local Health Unit of Biella","place":["Biella, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Martiadis","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Local Health Unit of Napoli 1 Centro","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Bianca","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maina","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Rosso","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00467.x","article-title":"Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder","volume":"9","author":"Kupka","year":"2007","journal-title":"Bipolar Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-019-0160-1","article-title":"Bipolar depression: a major unsolved challenge","volume":"8","author":"Baldessarini","year":"2020","journal-title":"Int J Bipolar Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00324.x","article-title":"Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia","volume":"9","author":"Malhi","year":"2007","journal-title":"Bipolar Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2008.00604.x","article-title":"Quality of life in bipolar disorder patients: a comparison with a general population sample","volume":"10","author":"Guti\u00e9rrez-Rojas","year":"2008","journal-title":"Bipolar Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0275-6","article-title":"Diagnosis, epidemiology and management of mixed states in bipolar disorder","volume":"29","author":"Fagiolini","year":"2015","journal-title":"CNS Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114296","article-title":"Symptoms of mania and anxiety do not contribute to suicidal ideation or behavior in the presence of bipolar depression","volume":"307","author":"Persons","year":"2022","journal-title":"Psychiatry Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.01.015","article-title":"A closer look at treatment resistant depression: is it due to a bipolar diathesis","volume":"84","author":"Sharma","year":"2005","journal-title":"J Affect Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064135","article-title":"Effectiveness of adjunctive antidepressant treatment for bipolar depression","volume":"356","author":"Sachs","year":"2007","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e100760","DOI":"10.1136\/gpsych-2022-100760","article-title":"Bipolar depression: a review of treatment options","volume":"35","author":"Levenberg","year":"2022","journal-title":"Gen Psychiatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13036","article-title":"The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary","volume":"22","author":"Malhi","year":"2020","journal-title":"Bipolar Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111408461","article-title":"Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis","volume":"26","author":"De Fruyt","year":"2012","journal-title":"J Psychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12026","article-title":"Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review","volume":"15","author":"Sienaert","year":"2013","journal-title":"Bipolar Disord"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1192\/bjp.bp.107.048504","article-title":"Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials","volume":"194","author":"Geddes","year":"2009","journal-title":"Br J Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09r05385gre","article-title":"Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis","volume":"72","author":"Sidor","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.03.030","article-title":"Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis","volume":"269","author":"Bahji","year":"2020","journal-title":"J Affect Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00438","article-title":"Predictors of treatment resistance across different clinical subtypes of depression: comparison of unipolar vs. bipolar cases","volume":"11","author":"Fornaro","year":"2020","journal-title":"Front Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.04.058","article-title":"Lithium in the treatment of acute bipolar depression: A systematic review and meta-analysis","volume":"308","author":"Rakofsky","year":"2022","journal-title":"J Affect Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0193-953x(05)70285-9","article-title":"Treatment-resistant bipolar depression","volume":"19","author":"Sachs","year":"1996","journal-title":"Psychiatr Clin North Am"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2009.01471.x","article-title":"Treatment-resistant bipolar depression: towards a new definition","volume":"120","author":"Pacchiarotti","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"B21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/1570159x13666150630171954","article-title":"Pharmacological approaches for treatment-resistant bipolar disorder","volume":"13","author":"Poon Hui","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1192\/bjp.2019.36","article-title":"Treatment-resistant and multi- therapy-resistant criteria for bipolar depression: Consensus definition","volume":"214","author":"Hidalgo-Mazzei","year":"2019","journal-title":"Br J Psychiatry"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1017\/9781108975292","volume-title":"Essential Psychopharmacology \u2013 Prescriber\u2019s Guide","author":"Stahl","year":"2021"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jpsychires.2016.03.012","article-title":"Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts","volume":"78","author":"Suppes","year":"2016","journal-title":"J Psychiatr Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13137","article-title":"Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression","volume":"74","author":"Kato","year":"2020","journal-title":"Psychiatry Clin Neurosci"},{"key":"B27","article-title":"Diagnostic and statistical manual of mental disorders","volume-title":"Text Revision: DSM-5-TR","year":"2022"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000064","article-title":"Oral SAMe in persistent treatment-refractory bipolar depression: a double-blind, randomized clinical trial","volume":"34","author":"Murphy","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13296","article-title":"REAL-ESK Study Group. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X22666240129095852","article-title":"Cariprazine augmentation in treatment-resistant bipolar depression: data from a retrospective observational study","volume":"22","author":"Teobaldi","year":"2024","journal-title":"Curr Neuropharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/YIC.0b013e32833c4ceb","article-title":"Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. Int","volume":"25","author":"Mendlewicz","year":"2010","journal-title":"Clin Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.124","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics","volume":"283","author":"Heerlein","year":"2021","journal-title":"J Affect Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.11.004","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Healthcare resource utilization","volume":"298","author":"Heerlein","year":"2022","journal-title":"J Affect Disord"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1102","article-title":"The impact of treatment-resistant depression on health care utilization and costs","volume":"63","author":"Crown","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ijnp\/pyy052","article-title":"The impact of (the concept of) treatment-resistant depression: an opinion review","volume":"22","author":"Demyttenaere","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12888-021-03220-3","article-title":"Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis","volume":"21","author":"Kadakia","year":"2021","journal-title":"BMC Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/YIC.0000000000000500","article-title":"Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis","volume":"39","author":"Jain","year":"2024","journal-title":"Int Clin Psychopharmacol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4088\/JCP.14m09410","article-title":"Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial","volume":"76","author":"McIntyre","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e301165","DOI":"10.1136\/bmjment-2024-301165","article-title":"Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis","volume":"27","author":"Lin","year":"2024","journal-title":"BMJ Ment Health"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2900-0","article-title":"Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid","volume":"226","author":"Calabrese","year":"2013","journal-title":"Psychopharmacol (Berl)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jad.2007.05.020","article-title":"Impact of anxiety disorder comorbidity on quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes","volume":"105","author":"Albert","year":"2008","journal-title":"J Affect Disord"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X20666220706104117","article-title":"Comorbidities in youth with bipolar disorder: clinical features and pharmacological management","volume":"21","author":"Sesso","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.17306","article-title":"Antidepressants in bipolar depression: an enduring controversy","volume":"17","author":"Gitlin","year":"2019","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13494","article-title":"Concept article: Antidepressant-induced destabilization in bipolar illness mediated by serotonin 3 receptor (5HT3)","volume":"26","author":"Aydin","year":"2024","journal-title":"Bipolar Disord"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1744056\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:42:46Z","timestamp":1771483366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1744056\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":46,"alternative-id":["10.3389\/fpsyt.2026.1744056"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1744056","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1744056"}}